Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company ...
The first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor – now given the somewhat tongue-twisting brand name of Ohtuvayre – is the first inhaled product with a novel mechanism of action ...
Ritedose is the development partner and manufacturer of Ohtuvayre (ensifentrine)*, the first inhaled product with a novel mechanism of action in more than 20 years for the maintenance treatment of ...
The analyses are published in the CHEST Annual Meeting on-line supplement. Ohtuvayre (ensifentrine) is a first-in-class selective dual inhibitor of the enzymes phosphodiesterase three and ...
In June, the Food and Drug Administration (FDA) approved Ohtuvayre (ensifentrine), the company's lead candidate. Verona’s stock has surged 36.8% YTD, outperforming the broader market's gain.
Hosted on MSN3mon
Verona (VRNA) Stock Surges 36% in the Past Month: Here's WhyShares of Verona Pharma VRNA have soared 36.3% since the past month, all thanks to the FDA’s approval of its lead pipeline drug in chronic obstructive pulmonary disease (COPD) indication.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback